Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Dennis Podlesak sold 19,200 shares of SNDX on 14 August at $14.19 per share, worth a total of $273K. They now own 191,763 SNDX shares, or a 9% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
